Company intelligence / Profile preview

QL Biopharm

Beijing, China

Ownership: Private
Development stage: Other

Overview

QL Biopharm's lead candidate zovaglutide (ZT002), a novel ultra long-acting GLP-1 receptor agonist with monthly dosing, demonstrated superior efficacy in Phase 2 trials with patients receiving 160 mg monthly experiencing 13.8% body weight reduction at 24 weeks, compared to 2.4% placebo. The company also reported improved cardiometabolic risk indicators and safety profiles consistent with the GLP-1 class. Phase 3 trials are now underway.[2][8]

Therapeutic areas: EndocrinologyNeurologyGastroenterology
Modalities: PeptidesRecombinant protein
Industry: Biotech

Beyond the preview

Go deeper on QL Biopharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QL Biopharm.

Explore the full profile